Skip Navigation

  1. Acerca de Nosotros
    1. Visión General
    2. Historia
    3. Oficinas
  2. Nuestra Experiencia
    1. Áreas de Trabajo
      1. Patentes
      2. Marcas
      3. Derecho de Autor
      4. Derecho Corporativo y Mercantil
      5. Litigio de Propiedad Intelectual y Resolución Alternativa de Disputas
      6. Práctica Regulatoria
      7. Otorgamiento de Licencias, Transferencia de Tecnología y Franquicias
      8. Anti-Piratería, Anti-Falsificación & Aplicación
    2. Grupos de la Industria
      1. Grupo de Abogados en Medios, Deportes y Entretenimiento
      2. Grupo de Abogados e Ingenieros en Ciencias de la Vida
  3. Nuestra Gente
    1. Socios
      1. Sergio L. Olivares, Sr. † (1931-2010)
      2. Sergio L. Olivares, Jr.
      3. Luis C. Schmidt
      4. César Ramos, Jr.
      5. Antonio Belaunzarán
      6. Gustavo A. Alcocer
      7. José Ignacio de Santiago
      8. Alejandro Luna
      9. Alonso Camargo
      10. Daniel Sánchez
    2. Asociados (A - M)
      1. Osvaldo Amaral
      2. Armando Arenas
      3. Sofía Arroyo
      4. Guillermo Ballesteros
      5. Varinia Calleros
      6. Abraham Diaz
      7. Georgina Flores
      8. Pedro Herrera
      9. Carlos Maya
    3. Asociados (N - Z)
      1. Mauricio Narváez
      2. Víctor Ramírez
      3. Sergio Rangel
      4. Maria del Carmen Sada
      5. Juan Luis Serrano
      6. Guillermo Treviño
      7. Carlos Woodworth
    4. Abogados / Ingenieros
    5. Administración de la firma
  4. Conocimiento & Recursos
    1. Artículos y Estudios de Casos
      1. Artículos sobre Marcas
        1. Use requirements
        2. Approach to composite marks changed, again
        3. Life Sciences Handbook 2011 - Country Q&A
        4. Mexico should accept secondary meaning
        5. Getting the Deal Through - Trademarks 2011
        6. Pharmaceutical Trademarks 2010/2011 - A Global Guide
        7. No legal basis for banning names derived from INNs
        8. How Latin America tackles cutting-edge IP issues
        9. Specialised IP court corrects IMPI
        10. Protecting trade dress
        11. 43 more items...
      2. Artículos sobre Patentes
        1. Mexican Linkage Gazette April 2011
        2. Mexico issues regulations to approve biologic drugs
        3. Latin America Roundtable
        4. New regulations pending
        5. The International Comparative Guide
        6. Marketing authorization for pharmaceutical
        7. Approval of follow-on biologics in Mexico
        8. Patent Prosecution Highway in Mexico
        9. Life Sciences Handbook 2011 - Country Q&A
        10. Data Package Exclusivity (DPE)
        11. 35 more items...
      3. Artículos sobre Derecho de Autor
        1. Publicidad en redes sociales
        2. Technology challenges digital rights
        3. Exceptions to copyright protection and the permitted uses of copyright works in the hi-tech and digital sectors
        4. Derechos sobre producción audiovisual
        5. How Latin America tackles cutting-edge IP issues
        6. Copyright Litigation 2010
        7. Legislation and enforcement - Copyrights 2010
        8. Valuing folklore
        9. Protecting novel ideas
        10. Mexico's fair use balancing act
        11. 97 more items...
      4. Artículos sobre Derecho Corporativo
        1. Mexico issues Personal Data Protection Rules
        2. A practical cross-border
        3. New registry for security interests
        4. The International Comparative Legal Guide to: Merger Control 2011
        5. The International Comparative Legal Guide to: Merger Control 2010
        6. Due diligence issues to consider in M&A
        7. Income expectations in licensing
        8. The reasons for valuation
        9. Amendments proposed to franchise regulation
      5. Artículos sobre Litigio y RAD
        1. Scope of new specialised courts widened
        2. Reform of preliminary injunctions
        3. Mexican Patent Office excludes Formulation Patents from Linkage Gazette
        4. Mexico gets ready to approve biocomparable drugs
        5. Mexico's hotel for the stars highlights power in the name
        6. Supreme Court upholds the worth of formulation patents
        7. Getting the Deal Through - Patents 2010
        8. Getting the Deal Through Trademarks 2010
        9. Trademark enforcement
        10. Venues for appealing IMPI decisions
        11. 15 more items...
      6. Artículos sobre Derecho Regulatorio
        1. Recientes enmiendas a la Ley Federal de Protección al Consumidor
        2. Enmiendas en la Ley Federal de Protección al Consumidor
        3. Mexico issues Personal Data Protection Rules
        4. New Regulations Pending
        5. Marketing authorization for pharmaceutical products to foreign applicants
        6. Data Package Exclusivity (DPE)
        7. Supreme Court upholds the worth of formulation patents
        8. Pharmaceutical trademarks
        9. Framework for biotherapeutic products established
        10. Pharmaceutical Advertising 2009
        11. 4 more items...
      7. Artículos sobre Licencias y Transferencia de Tecnología
        1. Creating a secure franchise system
      8. Artículos sobre Anti-piratería y Anti-falsificación
        1. New register against counterfeits
        2. Beat the counterfeiters in Mexico
        3. Battling counterfeits through Customs
        4. Getting the Deal Through Trademarks 2010
        5. Enforcing plant variety rights in Mexico
        6. Pharmaceutical Trademarks 2009
        7. Internet Issues
        8. Anti-counterfeiting 2009
        9. Vegetal variety rights enforced
        10. New Customs rules lead to seizures
        11. 4 more items...
      9. Artículos en relación con Medios, Deportes y Entretenimiento
        1. Publicidad en redes sociales
        2. Whither Rental Rights?
        3. Improved protection for personalities
      10. Artículos en relación con Ciencias de la Vida
        1. Latin America Roundtable
        2. New regulations pending
        3. The International Comparative
        4. Approval of follow-on biologics in Mexico
        5. Global Pharmaceutical Linkage Regulations:
        6. Life Sciences Handbook 2011 - Country Q&A
        7. Supreme Court upholds the worth of formulation patents
        8. Repercussions expected on medicine advertising campaign in Mexico
        9. Framework for biotherapeutic products established
        10. Pharmaceutical Trademarks 2009
        11. 1 more item...
  5. Oficinas
  6. Eventos
  7. Contacto

Español » Conocimiento & Recursos » Artículos y Estudios de Casos » Artículos sobre Derecho Corporativo » Income expectations in licensing

Income expectations in licensing

por Carlos Woodworth
Managing Intellectual Property, International Briefings, June 2006
Technology transfer provides the scope for creativity in the organization and structure of what is usually a long-term relationship. The bottom line is always lasting profitability for the respective parties.
When setting a price for a technology transfer the initial objective should be to quantify the total size of the profitability pie to be generated by the combination of rights and resources which are expected to be contributed by the respective parties. There are many ways in which a licensor can realize a return on its investment in discovering, creating and developing the technology being licensed or otherwise transferred. However, a realistic approach to income expectations will facilitate a long-term relationship between the parties. It is the purpose of this briefing to outline specific criteria that should be considered to achieve a mutually satisfactory bottom line. Some of these are:
  1. Size of the relevant market: is the item resulting from the licensed technology utilized by the general public, or is it a relatively specialized item that is important to only a narrow sector of the population, or even to a limited geographical region?
  2. Dynamism of the market. This depends on the underlying sector of the economy that is expected to be caught as a result of the licence. Is it a market that is notably expanding and that may be expected to grow further? Or is this a flat market because of the excess production capacity, too many competitors or even general technological obsolesce?
  3. Characteristics of the technology to be licensed. Is the licensed technology a unique one, that is, or is expected to, create a new expanding market? Is a pioneer IP right involved? Or is it only an evolutionary refinement of something relatively standard?
  4. Quality of contribution by the owner of the technology. Does the proprietor enjoy a well-recognized reputation as an innovator and continuing source of useful ideas and improvements? Is it known to defend its rights vigorously against infringers?
  5. Assets expected to be contributed by technology recipient. Is the recipient financially capable, an efficient manufacturer, and/or does it possess a sound marketing, organization? If properly motivated, is it likely to maximize the potential of the relevant technology?
  6. General state of the economy. Are conditions considered to be healthy, expanding, in recession or in recovery? Is there an economic indicator, tax incentive, legal framework that could affect the contemplated business of the licensing parties?
Notwithstanding these basic criteria, an argument sometimes raised by a proprietor when it is offering an invention for license is that is has spent enormous time, effort and money to create and develop the technology involved. A realistic contra argument is that these are sunk costs to the licensor that are irrelevant to the licensee, who is only interested in the future profitability the licensed technology is likely to generate. The risk element is very important to determine profit sharing. Generally it is the licensee who bears the principal risk, since it is usually exposed to unknown elements in the marketplace that might help or hinder the introduction of the licensed product.
In summary, these criteria should help the parties conclude that their portion of the profit pie is not always mandated by a standard practice formula, but rather by practical approaches that might help them make a business determination when licensing technology.